» Articles » PMID: 38463259

Formulation of Folate Receptor-Targeted Silibinin-Loaded Inhalable Chitosan Nanoparticles by the QbD Approach for Lung Cancer Targeted Delivery

Overview
Journal ACS Omega
Specialty Chemistry
Date 2024 Mar 11
PMID 38463259
Authors
Affiliations
Soon will be listed here.
Abstract

: Targeted delivery of chemotherapeutics by functionalized nanoparticles exhibits a wonderful prospect for cancer treatment. The main objective of this research was to develop folate receptor-targeted silibinin (SB)-loaded inhalable polymeric nanoparticles (FA-CS-SB-NPs) for the treatment of lung cancer. : The qbD approach was implemented to prepare SB-loaded nanoparticles. Folic acid was conjugated by electrostatic conjugation in an optimized batch. The therapeutic potentials of formulations were determined using a lung cancer cell-bearing rat model. : Optimized formulation exhibited a spherical surface with a mean particle size of 275 ± 1.20 nm, a PDI of 0.234 ± 0.07, a ζ-potential of 32.50 ± 0.21, an entrapment efficiency of 75.52 ± 0.87%, and a CDR of 63.25 ± 1.21% at 48 h. Aerodynamic behaviors such as the mass median aerodynamic diameter (MMAD) and geometric size distribution (GSD) were found to be 2.75 ± 1.02 and 3.15 ± 0.88 μm, respectively. After 24 h of incubation with FA-CS-SB-NPs, the IC50 value was found to be 24.5 g/mL. FA-SB-CS-NPs maintained a significantly higher deposition of SB in lung tissues. : Thus, the noninvasive nature and target specificity of FA-CS-SB-NPs pave the way for pulmonary delivery for treating lung cancer.

Citing Articles

Advances in controlled release drug delivery systems based on nanomaterials in lung cancer therapy: A review.

Fu J, Yu L, Wang Z, Chen H, Zhang S, Zhou H Medicine (Baltimore). 2025; 104(6):e41415.

PMID: 39928802 PMC: 11813027. DOI: 10.1097/MD.0000000000041415.


The Effects of Silibinin Combined With EGFR-TKIs in the Treatment of NSCLC.

Wang X Cancer Med. 2025; 14(3):e70643.

PMID: 39907159 PMC: 11795421. DOI: 10.1002/cam4.70643.


Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation.

Kassaee S, Richard D, Ayoko G, Islam N Nanomedicine (Lond). 2024; 19(25):2113-2133.

PMID: 39143915 PMC: 11486133. DOI: 10.1080/17435889.2024.2387530.

References
1.
Zou J, Su S, Chen Z, Liang F, Zeng Y, Cen W . Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy. Artif Cells Nanomed Biotechnol. 2019; 47(1):3456-3464. DOI: 10.1080/21691401.2019.1626863. View

2.
Ahmed T, Aljaeid B . Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther. 2016; 10:483-507. PMC: 4734734. DOI: 10.2147/DDDT.S99651. View

3.
Saremi S, Atyabi F, Akhlaghi S, Ostad S, Dinarvand R . Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation. Int J Nanomedicine. 2011; 6:119-28. PMC: 3026577. DOI: 10.2147/IJN.S15500. View

4.
Bhatnagar S, Chaudhary N, Katare D, Jain S . A non-surgical method for induction of lung cancer in Wistar rats using a combination of NNK and high dietary fats. Protoplasma. 2013; 250(4):919-29. DOI: 10.1007/s00709-012-0478-3. View

5.
Amirsaadat S, Pilehvar-Soltanahmadi Y, Zarghami F, Alipour S, Ebrahimnezhad Z, Zarghami N . Silibinin-loaded magnetic nanoparticles inhibit hTERT gene expression and proliferation of lung cancer cells. Artif Cells Nanomed Biotechnol. 2017; 45(8):1649-1656. DOI: 10.1080/21691401.2016.1276922. View